You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 
2019

Breast Cancer: Medication Use to Reduce Risk in Women Not at Increased Risk

Description of Resource: 
The U.S. Preventive Services Task Force (USPSTF) recommends against the routine use of risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, in women who are not at increased risk for breast cancer. This is a D recommendation, which means the USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
U.S. Preventive Services Task Force
Developer Type: 
Federal Government
Healthy People 2020 Topic Area(s): 
Cancer
Healthy People 2020 Objectives: 
Resource Type: 
Systematic Review
Citation: 
U.S. Preventive Services Task Force. Breast Cancer: Medication Use to Reduce Risk [Internet]. 2019 Sep [cited 2019 Sep 6]. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1